{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T21:59:45Z","timestamp":1791928785297,"version":"4.3.4"},"reference-count":67,"publisher":"Association for Research in Vision and Ophthalmology (ARVO)","issue":"4","license":[{"start":{"date-parts":[[2021,4,2]],"date-time":"2021-04-02T00:00:00Z","timestamp":1617321600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Invest. Ophthalmol. Vis. Sci."],"published-print":{"date-parts":[[2021,4,2]]},"DOI":"10.1167\/iovs.62.4.3","type":"journal-article","created":{"date-parts":[[2021,4,2]],"date-time":"2021-04-02T13:31:27Z","timestamp":1617370287000},"page":"3","source":"Crossref","is-referenced-by-count":39,"title":["Targeting the YAP\/TAZ Pathway in Uveal and Conjunctival Melanoma With Verteporfin"],"prefix":"10.1167","volume":"62","author":[{"given":"Niels J.","family":"Brouwer","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, Retina Service, Angiogenesis Laboratory, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, MA, United States"},{"name":"Department of Ophthalmology, Leiden University Medical Center, Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleni K.","family":"Konstantinou","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Retina Service, Angiogenesis Laboratory, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, MA, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evangelos S.","family":"Gragoudas","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Retina Service, Angiogenesis Laboratory, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, MA, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Marinkovic","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Leiden University Medical Center, Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregorius P. M.","family":"Luyten","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Leiden University Medical Center, Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivana K.","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Retina Service, Angiogenesis Laboratory, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, MA, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martine J.","family":"Jager","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Leiden University Medical Center, Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Demetrios G.","family":"Vavvas","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Retina Service, Angiogenesis Laboratory, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, MA, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"27","reference":[{"key":"bib1","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.1016\/j.ophtha.2011.01.040","article-title":"Uveal melanoma: trends in incidence, treatment, and survival","volume":"118","author":"Singh","year":"2011","journal-title":"Ophthalmology"},{"key":"bib2","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/0039-6257(88)90173-7","article-title":"Epidemiologic aspects of uveal melanoma","volume":"32","author":"Egan","year":"1988","journal-title":"Surv Ophthalmol"},{"key":"bib3","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1038\/eye.2016.275","article-title":"Uveal melanoma: relatively rare but deadly cancer","volume":"31","author":"Kaliki","year":"2017","journal-title":"Eye (Lond)"},{"key":"bib4","doi-asserted-by":"publisher","first-page":"4666","DOI":"10.1167\/iovs.06-0659","article-title":"Proton beam irradiation of uveal melanomas: the first 30 years. The Weisenfeld Lecture","volume":"47","author":"Gragoudas","year":"2006","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"bib5","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1016\/j.ajo.2004.07.006","article-title":"The Collaborative Ocular Melanoma Study (COMS) randomized trial of pre-enucleation radiation of large choroidal melanoma: IV. Ten-year mortality findings and prognostic factors. COMS report number 24","volume":"138","author":"Hawkins","year":"2004","journal-title":"Am J Ophthalmol"},{"key":"bib6","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1038\/eye.2012.126","article-title":"Progress in the management of patients with uveal melanoma. The 2012 Ashton Lecture","volume":"26","author":"Damato","year":"2012","journal-title":"Eye (Lond)"},{"key":"bib7","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1001\/jamaophthalmol.2018.2466","article-title":"Survival rates in patients after treatment for metastasis from uveal melanoma","volume":"136","author":"Lane","year":"2018","journal-title":"JAMA Ophthalmol"},{"key":"bib8","first-page":"3399","article-title":"Population-based assessment of clinical characteristics predicting outcome of conjunctival melanoma in whites","volume":"43","author":"Tuomaala","year":"2002","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"bib9","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1016\/S0002-9394(02)02288-2","article-title":"Conjunctival melanoma: is it increasing in the United States?","volume":"135","author":"Yu","year":"2003","journal-title":"Am J Ophthalmol"},{"key":"bib10","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1136\/bjo.2009.157933","article-title":"Time trends in the incidence of conjunctival melanoma in Sweden","volume":"93","author":"Triay","year":"2009","journal-title":"Br J Ophthalmol"},{"key":"bib11","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1586\/17469899.2014.921119","article-title":"Management of conjunctival malignant melanoma: a review and update","volume":"9","author":"Wong","year":"2014","journal-title":"Expert Rev Ophthalmol"},{"key":"bib12","first-page":"471","article-title":"Conjunctival melanoma: risk factors for recurrence, exenteration, metastasis, and death in 150 consecutive patients","volume":"98","author":"Shields","year":"2000","journal-title":"Trans Am Ophthalmol Soc"},{"key":"bib13","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1136\/bjophthalmol-2017-311082","article-title":"Treatment of conjunctival melanoma in a Dutch referral centre","volume":"102","author":"Brouwer","year":"2018","journal-title":"Br J Ophthalmol"},{"key":"bib14","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1136\/bjo.86.2.163","article-title":"Prognostic value of clinical and histopathological parameters in conjunctival melanomas: a retrospective study","volume":"86","author":"Anastassiou","year":"2002","journal-title":"Br J Ophthalmol"},{"key":"bib15","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1038\/nature07586","article-title":"Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi","volume":"457","author":"Van Raamsdonk","year":"2009","journal-title":"Nature"},{"key":"bib16","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1056\/NEJMoa1000584","article-title":"Mutations in GNA11 in uveal melanoma","volume":"363","author":"Van Raamsdonk","year":"2010","journal-title":"N Engl J Med"},{"key":"bib17","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1038\/ng.3549","article-title":"Recurrent activating mutations of G-protein-coupled receptor CYSLTR2 in uveal melanoma","volume":"48","author":"Moore","year":"2016","journal-title":"Nat Genet"},{"key":"bib18","doi-asserted-by":"publisher","first-page":"4624","DOI":"10.18632\/oncotarget.v7i4","article-title":"Deep sequencing of uveal melanoma identifies a recurrent mutation in PLCB4","volume":"7","author":"Johansson","year":"2016","journal-title":"Oncotarget"},{"key":"bib19","doi-asserted-by":"publisher","first-page":"100800","DOI":"10.1016\/j.preteyeres.2019.100800","article-title":"Uveal melanoma: Towards a molecular understanding","volume":"75","author":"Smit","year":"2019","journal-title":"Prog Retin Eye Res"},{"key":"bib20","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1097\/00008390-200412000-00003","article-title":"BRAF mutations are detectable in conjunctival but not uveal melanomas","volume":"14","author":"Spendlove","year":"2004","journal-title":"Melanoma Res"},{"key":"bib21","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1038\/bjc.2013.312","article-title":"TERT promoter mutations in ocular melanoma distinguish between conjunctival and uveal tumours","volume":"109","author":"Griewank","year":"2013","journal-title":"Br J Cancer"},{"key":"bib22","doi-asserted-by":"publisher","first-page":"6821","DOI":"10.1158\/1078-0432.CCR-08-0575","article-title":"KIT gene mutations and copy number in melanoma subtypes","volume":"14","author":"Beadling","year":"2008","journal-title":"Clin Cancer Res"},{"key":"bib23","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1038\/s41416-018-0046-5","article-title":"NF1 mutations in conjunctival melanoma","volume":"118","author":"Scholz","year":"2018","journal-title":"Br J Cancer"},{"key":"bib24","doi-asserted-by":"publisher","first-page":"3143","DOI":"10.1158\/1078-0432.CCR-13-0163","article-title":"Conjunctival melanomas harbor BRAF and NRAS mutations and copy number changes similar to cutaneous and mucosal melanomas","volume":"19","author":"Griewank","year":"2013","journal-title":"Clin Cancer Res"},{"key":"bib25","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1001\/jamaophthalmol.2017.4837","article-title":"Molecular characteristics of conjunctival melanoma using whole-exome sequencing","volume":"135","author":"Swaminathan","year":"2017","journal-title":"JAMA Ophthalmol"},{"issue":"7","key":"bib26","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.3390\/cancers11071032","article-title":"So close, yet so far: discrepancies between uveal and other melanomas. A Position Paper from UM Cure 2020","volume":"11","author":"Rodrigues","year":"2019","journal-title":"Cancers (Basel)"},{"key":"bib27","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/nrc3876","article-title":"The emerging roles of YAP and TAZ in cancer","volume":"15","author":"Moroishi","year":"2015","journal-title":"Nat Rev Cancer"},{"key":"bib28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1101\/gad.274027.115","article-title":"Mechanisms of Hippo pathway regulation","volume":"30","author":"Meng","year":"2016","journal-title":"Genes Dev"},{"key":"bib29","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1111\/pcmr.2014.27.issue-4","article-title":"In melanoma, Hippo signaling is affected by copy number alterations and YAP1 overexpression impairs patient survival","volume":"27","author":"Menzel","year":"2014","journal-title":"Pigment Cell Melanoma Res"},{"key":"bib30","first-page":"662","article-title":"High expression of TAZ\/YAP promotes the progression of malignant melanoma and affects the postoperative survival of patients","volume":"73","author":"Feng","year":"2018","journal-title":"Pharmazie"},{"key":"bib31","first-page":"357","article-title":"Higher irradiance and photodynamic therapy for age-related macular degeneration (an AOS thesis)","volume":"106","author":"Miller","year":"2008","journal-title":"Trans Am Ophthalmol Soc"},{"key":"bib32","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1101\/gad.192856.112","article-title":"Genetic and pharmacological disruption of the TEAD-YAP complex suppresses the oncogenic activity of YAP","volume":"26","author":"Liu-Chittenden","year":"2012","journal-title":"Genes Dev"},{"key":"bib33","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.exer.2014.04.011","article-title":"The clinically used photosensitizer Verteporfin (VP) inhibits YAP-TEAD and human retinoblastoma cell growth in vitro without light activation","volume":"124","author":"Brodowska","year":"2014","journal-title":"Exp Eye Res"},{"key":"bib34","doi-asserted-by":"publisher","first-page":"7602","DOI":"10.1038\/s41598-017-07632-8","article-title":"Verteporfin inhibits growth of human glioma in vitro without light activation","volume":"7","author":"Al-Moujahed","year":"2017","journal-title":"Sci Rep"},{"key":"bib35","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1016\/j.ccr.2014.04.017","article-title":"Mutant Gq\/11 promote uveal melanoma tumorigenesis by activating YAP","volume":"25","author":"Yu","year":"2014","journal-title":"Cancer Cell"},{"key":"bib36","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1016\/j.ccr.2014.04.016","article-title":"Hippo-independent activation of YAP by the GNAQ uveal melanoma oncogene through a trio-regulated rho GTPase signaling circuitry","volume":"25","author":"Feng","year":"2014","journal-title":"Cancer Cell"},{"key":"bib37","doi-asserted-by":"publisher","first-page":"6180","DOI":"10.1167\/iovs.10-5677","article-title":"Lack of oncogenic GNAQ mutations in melanocytic lesions of the conjunctiva as compared to uveal melanoma","volume":"51","author":"Dratviman-Storobinsky","year":"2010","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"bib38","first-page":"16","article-title":"Multifaceted regulation and functions of YAP\/TAZ in tumors (review)","volume":"40","author":"Liu","year":"2018","journal-title":"Oncol Rep"},{"key":"bib39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.7150\/jca.27472","article-title":"The efficiency of verteporfin as a therapeutic option in pre-clinical models of melanoma","volume":"10","author":"Lui","year":"2019","journal-title":"J Cancer"},{"key":"bib40","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1038\/jid.2013.319","article-title":"Pro-invasive activity of the Hippo pathway effectors YAP and TAZ in cutaneous melanoma","volume":"134","author":"Nallet-Staub","year":"2014","journal-title":"J Invest Dermatol"},{"key":"bib41","doi-asserted-by":"publisher","first-page":"6209","DOI":"10.1038\/s41598-020-63391-z","article-title":"YAP activity is not associated with survival of uveal melanoma patients and cell lines","volume":"10","author":"Kim","year":"2020","journal-title":"Sci Rep"},{"key":"bib42","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1136\/bjophthalmol-2014-305047","article-title":"Prognostic parameters in uveal melanoma and their association with BAP1 expression","volume":"98","author":"van Essen","year":"2014","journal-title":"Br J Ophthalmol"},{"key":"bib43","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1126\/science.1194472","article-title":"Frequent mutation of BAP1 in metastasizing uveal melanomas","volume":"330","author":"Harbour","year":"2010","journal-title":"Science"},{"key":"bib44","doi-asserted-by":"publisher","first-page":"204\u2013220 e215","DOI":"10.1016\/j.ccell.2017.07.003","article-title":"Integrative analysis identifies four molecular and clinical subsets in uveal melanoma","volume":"32","author":"Robertson","year":"2017","journal-title":"Cancer Cell"},{"key":"bib45","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1007\/s00262-017-1991-1","article-title":"Genetic evolution of uveal melanoma guides the development of an inflammatory microenvironment","volume":"66","author":"Gezgin","year":"2017","journal-title":"Cancer Immunol Immunother"},{"key":"bib46","doi-asserted-by":"publisher","first-page":"e0116371","DOI":"10.1371\/journal.pone.0116371","article-title":"Digital PCR validates 8q dosage as prognostic tool in uveal melanoma","volume":"10","author":"Versluis","year":"2015","journal-title":"PLoS One"},{"key":"bib47","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1038\/modpathol.2014.43","article-title":"Clinical significance of immunohistochemistry for detection of BAP1 mutations in uveal melanoma","volume":"27","author":"Koopmans","year":"2014","journal-title":"Mod Pathol"},{"issue":"7","key":"bib48","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.3390\/cancers11071004","article-title":"Ischemia is related to tumour genetics in uveal melanoma","volume":"11","author":"Brouwer","year":"2019","journal-title":"Cancers (Basel)"},{"issue":"7","key":"bib49","doi-asserted-by":"publisher","first-page":"979","DOI":"10.3390\/cancers11070979","article-title":"Tumour angiogenesis in uveal melanoma is related to genetic evolution","volume":"11","author":"Brouwer","year":"2019","journal-title":"Cancers (Basel)"},{"key":"bib50","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1002\/(ISSN)1097-0215","article-title":"Establishment and characterization of an uveal-melanoma cell line","volume":"62","author":"De Waard-Siebinga","year":"1995","journal-title":"Int J Cancer"},{"key":"bib51","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1002\/(ISSN)1097-0215","article-title":"Establishment and characterization of primary and metastatic uveal melanoma cell lines","volume":"66","author":"Luyten","year":"1996","journal-title":"Int J Cancer"},{"key":"bib52","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1002\/(ISSN)1097-0215","article-title":"Melanomas that develop within the eye inhibit lymphocyte proliferation","volume":"73","author":"Verbik","year":"1997","journal-title":"Int J Cancer"},{"key":"bib53","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1016\/j.molonc.2014.06.004","article-title":"Establishment of novel cell lines recapitulating the genetic landscape of uveal melanoma and preclinical validation of mTOR as a therapeutic target","volume":"8","author":"Amirouchene-Angelozzi","year":"2014","journal-title":"Mol Oncol"},{"key":"bib54","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.exer.2005.04.018","article-title":"Establishment of two cell lines derived from conjunctival melanomas","volume":"81","author":"Nareyeck","year":"2005","journal-title":"Exp Eye Res"},{"key":"bib55","first-page":"399","article-title":"Non-fastidious, melanoma-specific CD8+ cytotoxic T lymphocytes from choroidal melanoma patients","volume":"38","author":"Huang","year":"1994","journal-title":"Cancer Immunol Immunother"},{"key":"bib56","first-page":"T5","article-title":"Uveal melanoma cell lines: where do they come from? (An American Ophthalmological Society Thesis)","volume":"114","author":"Jager","year":"2016","journal-title":"Trans Am Ophthalmol Soc"},{"key":"bib57","first-page":"2816","article-title":"Verteporfin induces apoptosis and eliminates cancer stem-like cells in uveal melanoma in the absence of light activation","volume":"6","author":"Ma","year":"2016","journal-title":"Am J Cancer Res"},{"key":"bib58","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1016\/j.chembiol.2012.07.005","article-title":"Identification of serum-derived sphingosine-1-phosphate as a small molecule regulator of YAP","volume":"19","author":"Miller","year":"2012","journal-title":"Chem Biol"},{"key":"bib59","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1016\/j.ccr.2014.05.028","article-title":"GNAQ\/11 mutations in uveal melanoma: is YAP the key to targeted therapy?","volume":"25","author":"Field","year":"2014","journal-title":"Cancer Cell"},{"key":"bib60","doi-asserted-by":"publisher","first-page":"e1021441","DOI":"10.1080\/23723556.2015.1021441","article-title":"The Hippo effector YAP regulates the response of cancer cells to MAPK pathway inhibitors","volume":"3","author":"Lin","year":"2016","journal-title":"Mol Cell Oncol"},{"key":"bib61","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1002\/ijc.v143.9","article-title":"A time for YAP1: tumorigenesis, immunosuppression and targeted therapy","volume":"143","author":"Shibata","year":"2018","journal-title":"Int J Cancer"},{"key":"bib62","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1016\/j.cell.2015.07.061","article-title":"Non-genomic and immune evolution of melanoma acquiring MAPKi resistance","volume":"162","author":"Hugo","year":"2015","journal-title":"Cell"},{"key":"bib63","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1038\/ng.3218","article-title":"The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies","volume":"47","author":"Lin","year":"2015","journal-title":"Nat Genet"},{"key":"bib64","doi-asserted-by":"publisher","first-page":"5686","DOI":"10.1158\/1078-0432.CCR-18-3382","article-title":"HDAC inhibition enhances the in vivo efficacy of MEK inhibitor therapy in uveal melanoma","volume":"25","author":"Faiao-Flores","year":"2019","journal-title":"Clin Cancer Res"},{"key":"bib65","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1158\/2326-6066.CIR-17-0320","article-title":"YAP-Induced PD-L1 expression drives immune evasion in BRAFi-resistant melanoma","volume":"6","author":"Kim","year":"2018","journal-title":"Cancer Immunol Res"},{"key":"bib66","doi-asserted-by":"publisher","first-page":"462","DOI":"10.15252\/embj.201592081","article-title":"Actin remodeling confers BRAF inhibitor resistance to melanoma cells through YAP\/TAZ activation","volume":"35","author":"Kim","year":"2016","journal-title":"EMBO J"},{"key":"bib67","doi-asserted-by":"publisher","first-page":"110257","DOI":"10.18632\/oncotarget.v8i66","article-title":"Inhibition of YAP function overcomes BRAF inhibitor resistance in melanoma cancer stem cells","volume":"8","author":"Fisher","year":"2017","journal-title":"Oncotarget"}],"container-title":["Investigative Opthalmology & Visual Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/iovs.arvojournals.org\/article.aspx?articleid=2772448","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T21:31:27Z","timestamp":1791927087000},"score":1,"resource":{"primary":{"URL":"https:\/\/iovs.arvojournals.org\/article.aspx?articleid=2772448"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,2]]},"references-count":67,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,4,1]]}},"URL":"https:\/\/doi.org\/10.1167\/iovs.62.4.3","relation":{},"ISSN":["1552-5783"],"issn-type":[{"value":"1552-5783","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4,2]]}}}